Are Myosin Inhibitors the Future of HCM Management? - European Medical Journal

Are Myosin Inhibitors the Future of HCM Management?


The EMJ Podcast | Bonus Episode

This podcast episode explores new advances in treating obstructive hypertrophic cardiomyopathy (HCM) and the role of myosin inhibitors, and provides an overview of the EXPLORER-HCM and VALOR-HCM clinical trials.

Spotify | Apple | Amazon MusicDownload MP3 (mp3, 30:58 mins)


Iacopo Olivotto, University of Florence, Italy, first discusses unmet medical needs, specifically regarding the unmet needs of patients and gaps in current treatment methods. The discussion then centres around the mechanism of action of myosin inhibitors, a first-in-class drug for HCM, recently approved by the European Medicines Agency (EMA).

The findings of current clinical trials are outlined, with results being linked to a reduced need for septal reduction therapy, in addition to improved quality of life for patients. Finally, case studies are presented, discussing the impact of treatments on the lives of patients with HCM, and how to best integrate new treatments into current practice.

The medical education podcast was sponsored by Myokardia and Bristol Myers Squibb.

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally